Pharsight

1. List of Tradjenta drug patents

Application	Filing Date	Opposition Party	Legal Status
EP10175188A	2015-12-11	Galenicum Health S.L.	Revoked
EP10175188A	2015-12-11	Generics (UK) Limited	Revoked
EP10175188A	2015-12-10	STADA Arzneimittel AG	Revoked
EP10175188A	2015-12-10	Hexal AG	Revoked
EP10175188A	2015-12-10	Teva Pharmaceutical Industries LTD.	Revoked
EP10175638A	2015-07-08	Generics [UK] Limited (trading as Mylan)	Revoked
EP10175638A	2015-07-08	STADA Arzneimittel AG	Revoked
EP10175638A	2015-07-07	Hexal AG	Revoked
EP10175638A	2015-07-07	Teva Pharmaceutical Industries Ltd.	Revoked
EP07728723A	2015-01-05	Hexal AG	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8673927	August, 2016	Terminated-Adverse Judgment	Boehringer Ingelheim Pharmaceuticals Inc.	Mylan Pharmaceuticals Inc.
US8846695	August, 2016	Terminated-Adverse Judgment	Boehringer Ingelheim Pharmaceuticals Inc.	Mylan Pharmaceuticals Inc.
US8853156	August, 2016	Terminated-Adverse Judgment	Boehringer Ingelheim Pharmaceuticals Inc.	Mylan Pharmaceuticals Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (4 months from now)
US8178541	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (4 months from now)
US8883805	BOEHRINGER INGELHEIM	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov, 2025 (2 years from now)
US11033552	BOEHRINGER INGELHEIM	DPP IV inhibitor formulations	May, 2027 (4 years from now)
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (4 years from now)
US9486526	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Aug, 2029 (6 years from now)
US10034877	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Aug, 2029 (6 years from now)
US8846695	BOEHRINGER INGELHEIM	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Jun, 2030 (7 years from now)
US8853156	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Mar, 2031 (7 years from now)

Exclusivity	Exclusivity Expiration
M (M)	Mar 30, 2023

Market Authorisation Date: 02 May, 2011

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by adm...

Dosage: TABLET;ORAL